VANCOUVER, British Columbia, May 3, 2011 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX-V:QLT) ("QLT" or the "Company") announced today positive preliminary results from its Phase 1b proof-of-concept ...
Leber congenital amaurosis (LCA) is a genetic condition with multiple causes, which causes severe reduction in vision from birth or early childhood onwards. Diagnosis is made on the basis of family ...
Please provide your email address to receive an email when new articles are posted on . No serious treatment-emergent adverse events were seen at 12 months. Patients who received a high dose of ...
Leber congenital amaurosis is a congenital retinal dystrophy present in approximately 1 of 80,000 births. Recently, there has been progress in gene therapy for this condition. In a recent study, ...
Researchers from the National Eye Institute (NEI) have developed a gene therapy that rescues cilia defects in retinal cells affected by a type of Leber congenital amaurosis (LCA), a disease that ...
MeiraGTx has recently received Rare Pediatric Disease Designation (RPDD) for four inherited retinal diseases (IRDs) reflecting the transformative therapeutic potential of the Company’s proprietary ...
LONDON and NEW YORK, Dec. 7, 2017 /PRNewswire/ -- MeiraGTx, a London and New York-based gene therapy company, today announced that the Offices of Orphan Products Development and Pediatric Therapeutics ...
Scientists at the UCL Institute of Ophthalmology have identified the mechanism behind a common inherited cause of severe sight loss in young children. The results also point to a potential new ...
Please provide your email address to receive an email when new articles are posted on . Opus Genetics received rare pediatric disease designation from the FDA for its ocular gene therapy designed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback